JB170
Based on 3 publication(s) in Google Scholar
JB170 is a potent and highly specific PROTAC-mediated AURORA-A (Aurora Kinase) degrader (DC50=28 nM) by linking Alisertib, to the Cereblon-binding molecule Thalidomide. JB170 preferentially binds AURORA-A (EC50=193 nM) over AURORA-B (EC50=1.4 µM). JB170-mediated S-phase arrest is caused specifically by AURORA-A depletion. JB170 has excellent ability to inhibit non-catalytic function of AURORA-A kinase.
(Pink: Aurora A ligand (HY-10971); Blue: Cereblon ligand (HY-103597); Black: linker).
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- Pureté: 98.70%
- CAS No.: 2705844-82-0
- Formule: C48H44ClFN8O11
- Masse moléculaire:963.36
-
Stockage:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Activité biologique
-
Chemical Information
-
Solvant et solubilité
- Pureté et documentation
- Références
-
Help & FAQs
Publications Citing Use of MedChemExpress (MCE) JB170
MoreVoir tous les produits spécifiques à Isoform PROTACs
MoreVoir tous les produits spécifiques à Isoform Aurora Kinase
More
Activité biologique
|
Aurora A 28 nM (DC50) |
Aurora A 99 nM (Kd) |
Aurora A 193 nM (EC50) |
Cereblon |
JB170 (1 μM; 24-72 hours; MV4-11 cells) mediates Aurora-A depletion inhibiting cancer cell survival[1].
JB170 (0.01-10 μM; 6 hours; MV4-11 cells) reduces AURORA-A levels [1].
JB170 (0.5 μM; 12 hours; MV4-11 cells) delays/arrests S-phase progression[1].
JB170 (0.5 μM; 0-72 hours; MV4-11 cells) induces apoptosis is exclusively caused by targeting AURORA-A[1].
JB170 (0.1 μM; 0-9 hours; IMR5 cells) shows rapid AURORA-A depletion. JB170 (0~1 μM; 6 hours; MV4-11 cells) strongly attenuates in mutants with respect to AURORA-A. JB170 (0.1 μM; 18 hours; MV4-11 cells) does not activate AURORA-A. JB170 (0~1 μM; 24 hours; IMR5 cells) largely abrogates AURORA-AT217D depletion. JB170 (1 μM; 4 days; IMR5 cells) mediates Aurora-A depletion inhibiting cancer cell survival. JB170 (IMR5 cells) reduces AURORA-A levels by lowering AURORA-A mRNA levels[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:MV4-11 cells
-
Concentration:1 µM
-
Incubation Time:24-72 hours
-
Result:After 72 hours, the number of viable cells was 32% of control levels.
-
Cell Line:MV4-11 cells
-
Concentration:0.01~10 μM
-
Incubation Time:6 hours
-
Result:Substantial degradation was observed at 100 nM and 1 µM.
-
Cell Line:MV4-11 cells
-
Concentration:0.5 µM
-
Incubation Time:0~72 hours
-
Result:Apoptosis was exclusively caused by targeting AURORA-A.
-
Cell Line:MV4-11 cells
-
Concentration:0.5 µM
-
Incubation Time:12 hours
-
Result:Delayed or arrested S-phase progression.
Chemical Information
-
CAS No. 2705844-82-0
-
Appearance Solid
-
Masse moléculaire 963.36
-
Formule C48H44ClFN8O11
-
Color Light yellow to yellow
-
SMILES
FC1=CC=CC(OC)=C1C2=NCC3=C(C4=C2C=C(C=C4)Cl)N=C(NC5=CC=C(C(OC)=C5)C(NCCOCCOCCNC(COC6=C7C(C(N(C7=O)C8CCC(NC8=O)=O)=O)=CC=C6)=O)=O)N=C3
-
Livraison
Room temperature in continental US; may vary elsewhere.
-
Stockage
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month
Publications (3)
-
Journal Impact Factor
-
Most Recent
-
Mol Cell
Splice-switching ASOs targeting the AURKA 5' UTR collapse an SRSF1-AURKA-MYC oncogenic circuit in pancreatic cancer. [Abstract]2026 Jan 8;86(1):60-77.e7. PMID: 41475344 -
-
Solvant et solubilité
DMSO : 100 mg/mL (103.80 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Pureté et documentation
-
Fiche technique (279 KB)
-
SDS (254 KB)
- English - EN (254 KB)
- Français - FR (254 KB)
- Deutsch - DE (254 KB)
- Norwegian - NO (254 KB)
- Español - ES (254 KB)
- Swedish - SV (254 KB)
- Italian - IT (254 KB)
- Korean - KR (254 KB)
- Portuguese - PT (254 KB)
-
Instruction de manipulation (2659 KB)
Références
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 1.0380 mL | 5.1902 mL | 10.3803 mL | 25.9508 mL |
| 5 mM | 0.2076 mL | 1.0380 mL | 2.0761 mL | 5.1902 mL | |
| 10 mM | 0.1038 mL | 0.5190 mL | 1.0380 mL | 2.5951 mL | |
| 15 mM | 0.0692 mL | 0.3460 mL | 0.6920 mL | 1.7301 mL | |
| 20 mM | 0.0519 mL | 0.2595 mL | 0.5190 mL | 1.2975 mL | |
| 25 mM | 0.0415 mL | 0.2076 mL | 0.4152 mL | 1.0380 mL | |
| 30 mM | 0.0346 mL | 0.1730 mL | 0.3460 mL | 0.8650 mL | |
| 40 mM | 0.0260 mL | 0.1298 mL | 0.2595 mL | 0.6488 mL | |
| 50 mM | 0.0208 mL | 0.1038 mL | 0.2076 mL | 0.5190 mL | |
| 60 mM | 0.0173 mL | 0.0865 mL | 0.1730 mL | 0.4325 mL | |
| 80 mM | 0.0130 mL | 0.0649 mL | 0.1298 mL | 0.3244 mL | |
| 100 mM | 0.0104 mL | 0.0519 mL | 0.1038 mL | 0.2595 mL |
JB170 Related Classifications
HY-141512 Related Classifications
Powered by Bioz